Adebrelimab with chemotherapy and radiation for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with advanced (stage III) non-small cell lung cancer that cannot be removed by surgery, with a large tumor or significant lymph node involvement
- No prior cancer treatment (chemotherapy, radiation, surgery, or targeted therapy)
- Good overall health and able to care for yourself with minimal assistance (ECOG 0–1)
- Expected to live at least 3 months
- Willing to use effective birth control if female and able to have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This trial tests a drug called Adebrelimab as a maintenance therapy after you finish chemotherapy and radiation (given in smaller, more frequent doses) for limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
This trial tests a combination of two immunotherapy drugs (adebrelimab and SHR-8068) plus chemotherapy for people with advanced or spreading non-small cell lung cancer that has certain genetic changes (STK11, KEAP1, or KRAS mutations). It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation therapy to see if it works better than standard treatment for people with extensive-stage small cell lung cancer who have not been treated before.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.